Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31670521 | 0.86 | GLP1R (0.33) | GLP1R | |
| SCHEMBL12209188 | 0.84 | KMT2A (0.35) | NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL31670505 | 0.78 | ADORA3 (0.35) | — | |
| SCHEMBL195356 | 0.78 | MAPK1 (0.37) | — | |
| SCHEMBL21098222 | 0.76 | — | — | |
| SCHEMBL20838961 | 0.75 | EHMT2 (0.31) | — | |
| SCHEMBL20838972 | 0.75 | PDE4D (0.34) | — | |
| SCHEMBL8256742 | 0.74 | BRD4 (0.38) | — | |
| SCHEMBL4071388 | 0.74 | TDP1 (0.36) | NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL20838959 | 0.74 | JAK2 (0.38) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724194-B1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-12-27 | — | — | EP | disclosed |
| CN-111712502-B | Substituted azetidine dihydro-thienopyrimidines and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11292799-B2 | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-04-05 | — | — | US | disclosed |
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-11 | — | — | US | disclosed |
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-11 | — | — | US | disclosed |
| EP-3724194-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2020-10-21 | — | — | EP | disclosed |
| CN-111712502-A | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-09-25 | — | — | CN | disclosed |
| WO-2019115774-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019115774-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292799-B2 | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE2A, PDE5A, PDE3A | GLP1R 967/4885NPC1 2871/4885MAPT 4310/4885 |
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE5A, PDE3A | GLP1R 967/4885NPC1 2871/4885MAPT 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.